|1.||Messori, Luigi: 5 articles (08/2015 - 03/2008)|
|2.||Reed, Sharon L: 5 articles (01/2015 - 06/2012)|
|3.||Debnath, Anjan: 4 articles (02/2015 - 06/2012)|
|4.||Savarino, Andrea: 3 articles (10/2015 - 07/2011)|
|5.||Modesti, Alessandra: 3 articles (08/2015 - 05/2010)|
|6.||Magherini, Francesca: 3 articles (08/2015 - 05/2010)|
|7.||McKerrow, James H: 3 articles (02/2015 - 06/2012)|
|8.||Spitz, Douglas R: 3 articles (01/2015 - 10/2011)|
|9.||Andrade, Rosa M: 3 articles (01/2015 - 06/2012)|
|10.||Huang, Hongbiao: 3 articles (01/2015 - 07/2014)|
12/30/1983 - "We conclude that both drugs are effective in rheumatoid arthritis and that the lesser toxicity with auranofin will make it a valuable addition to our therapeutic armamentarium."
06/01/2010 - "Since dysregulation of TLRs can lead to severe systemic inflammatory and joint destructive process in rheumatoid arthritis, auranofin-mediated modulation of TLR activation may have therapeutic potential against such diseases. "
03/01/1984 - "Auranofin is safe and effective for short- and long-term treatment of patients with rheumatoid arthritis. "
12/07/1985 - "The present study evaluates the long-term efficacy of auranofin in 46 patients with active rheumatoid arthritis and attempts to delineate further the results of drug monitoring concerning adverse reactions. "
05/01/1984 - "While patients have demonstrated clinical remission of rheumatoid arthritis in response to auranofin therapy, radiological studies have been inconclusive regarding its effect on the occurrence or progression of erosive lesions. "
02/15/1988 - "The proportions of patients showing 50% or greater improvement in tender joints, swollen joints, activity index, severity of pain, general health rating, and erythrocyte sedimentation rate (ESR) were similar for both auranofin-treated and GST-treated patients who completed the 48-week trial. "
01/01/1986 - "Efficacy of auranofin was apparent by 3 months after the start of treatment, as evidenced by improvement over baseline in number of tender joints, severity of pain, and erythrocyte sedimentation rate. "
01/01/2000 - "A statistically significant benefit was observed for auranofin when compared to placebo for tender joint scores, pain, patient and physician global assessments and ESR. "
10/01/1986 - "Auranofin was superior to placebo in the clinical (p = 0.003), functional (p = 0.001), and global (p = 0.007) composites and trended similarly in the pain composite (p = 0.021). "
11/01/1983 - "Of 193 patients who received any treatment, the only important improvement identified for either auranofin or GST was for pain/tenderness scores. "
|3.||Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
01/01/1990 - "The authors describe the results of prospective multicenter Soviet-American placebo-controlled 6-month investigations concerned with assessment of the therapeutic efficacy of auranofin in juvenile rheumatoid arthritis (JRA). "
01/01/1990 - "[The evaluation of the therapeutic efficacy of auranofin in juvenile rheumatoid arthritis (the results of Soviet-American research)]."
08/01/1988 - "The safety and efficacy of auranofin in the long-term treatment of children with juvenile rheumatoid arthritis was investigated in an open study of 14 patients. "
08/01/1991 - "Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial."
01/01/1986 - "Auranofin therapy in juvenile rheumatoid arthritis: a 48-week phase II study."
|4.||Asthma (Bronchial Asthma)
12/01/1991 - "We suggest that inhibition of bronchial hyperresponsiveness by auranofin is one of the mechanisms by which auranofin is effective against bronchial asthma."
07/01/1994 - "A recent double blind clinical trial in Japan has shown that auranofin (6 mg/day) is a useful treatment for patients with moderate to severe asthma. "
12/01/1991 - "Recently, in Japan, auranofin (6 mg/day) has been demonstrated to be a useful treatment for patients with moderate to severe asthma in a double-blind clinical trial. "
08/01/1996 - "Therefore this study has demonstrated that auranofin is useful as a steroid-sparing agent in the treatment of chronic corticosteroid-dependent asthma."
01/01/1988 - "An open study of auranofin in the treatment of steroid-dependent asthma."
06/01/1994 - "Degree of improvement of arthritis was better in the GST group, but the number of improved patients was greater in the auranofin group. "
11/01/1995 - "In order to study the pharmacological action site of auranofin during the functional suppression of leukocytes, especially neutrophils, we investigated the influence of auranofin on the calcium-45 (45Ca2+) uptake into peripheral blood neutrophils and peritoneal resident macrophages isolated from normal and adjuvant-induced arthritis (AA) rats. "
09/01/2000 - "These models are illustrated by reanalyzing three data sets, foremost a set of binary time series on auranofin therapy against arthritis. "
08/01/1997 - "Sixty-five patients with onset of arthritis after the age of 60 yr were randomized to either auranofin 3 mg b.i.d. "
09/01/1988 - "[Clinical effectiveness and tolerance of auranofin in patients with chronic polyarthritis. "
|2.||Gold Sodium Thiomalate (Sodium Aurothiomalate)
|8.||Histamine (Histamine Dihydrochloride)
|2.||Drug Therapy (Chemotherapy)